Publications by authors named "Mary Simcox"

Claim this Profile
C
CUE-101, a Novel E7-pHLA-IL2-Fc Fusion Protein, Enhances Tumor Antigen-Specific T-Cell Activation for the Treatment of HPV16-Driven Malignancies.
Steven N Quayle, Natasha Girgis, Dharma R Thapa, Zohra Merazga, Melissa M Kemp, Mary Ellen Simcox

Clin Cancer Res· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular basis of USP7 inhibition by selective small-molecule inhibitors.
Andrew P Turnbull, Stephanos Ioannidis, Wojciech W Krajewski, Adan Pinto-Fernandez, Claire Heride, Mary Simcox

Nature· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors.
Didier Meulendijks, Ulrik N Lassen, Lillian L Siu, Alwin D R Huitema, Vaios Karanikas, Mary E Simcox

Clin Cancer Res· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I monotherapy study of RG7212, a first-in-class monoclonal antibody targeting TWEAK signaling in patients with advanced cancers.
Ulrik N Lassen, Didier Meulendijks, Lilian L Siu, Vaios Karanikas, Morten Mau-Sorensen, Mary E Simcox

Clin Cancer Res· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RG7212 anti-TWEAK mAb inhibits tumor growth through inhibition of tumor cell proliferation and survival signaling and by enhancing the host antitumor immune response.
Xuefeng Yin, Leopoldo Luistro, Hua Zhong, Melissa Smith, Tom Nevins, Mary Simcox

Clin Cancer Res· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gene expression analysis in biomarker research and early drug development using function tested reverse transcription quantitative real-time PCR assays.
Sabine Lohmann, Andrea Herold, Tobias Bergauer, Anton Belousov, Gisela Betzl, Mary Simcox

Methods· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
Hong Yang, Brian Higgins, Kenneth Kolinsky, Kathryn Packman, William D Bradley, Mary Ellen Simcox

Cancer Res· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation.
Fei Su, William D Bradley, Qiongqing Wang, Hong Yang, Lizhong Xu, Mary Ellen Simcox

Cancer Res· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models.
Hong Yang, Brian Higgins, Kenneth Kolinsky, Kathryn Packman, Zenaida Go, Mary Ellen Simcox

Cancer Res· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis.
Lee A McDermott, Brian Higgins, Mary Simcox, Kin-Chun Luk, Tom Nevins

Bioorg Med Chem Lett· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RO4383596, an orally active KDR, FGFR, and PDGFR inhibitor: synthesis and biological evaluation.
Lee A McDermott, Mary Simcox, Brian Higgins, Tom Nevins, Kenneth Kolinsky

Bioorg Med Chem· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A new series of potent oxindole inhibitors of CDK2.
Kin-Chun Luk, Mary Ellen Simcox, Andy Schutt, Karen Rowan, Thelma Thompson

Bioorg Med Chem Lett· February 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
3
3,5,6-Trisubstituted naphthostyrils as CDK2 inhibitors.
Jin-Jun Liu, Apostolos Dermatakis, Christine Lukacs, Fred Konzelmann, Yi Chen, Mary Ellen Simcox

Bioorg Med Chem Lett· August 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis